U-turn confirms that the US cut-price oncology model is dead
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.
Esmo 2022 – Regeneron stakes its Lag3 claim
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
Sanofi’s oncology hopes crumble
The discontinuation of amcenestrant piles more pressure on the group’s chief executive, Paul Hudson.
No plain sailing for Novartis’s PD-1 plan
Getting the Swiss firm’s Beigene-derived anti-PD-1 MAb across the US finish line is proving harder than expected.
Asco 2022 – Abbvie goes back to basics with navitoclax
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
